Clinical Trials Logo
  1. Home
  2. Lymphoma, Extranodal NK-T-Cell
  3. NCT03051555

18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma

Lymphoma, Extranodal NK-T-Cell Clinical Trial

Official title:
18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma

Clinical Trial Summary

The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma can predict disease progression

Clinical Trial Description

In this study investigators develop a prognostic model based on 18F-FDG PET/CT and test its ability for prognostic value in patients with DLBCL. PET/ CT scans evaluation using the liver SUVmax as reference. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold or new 18F-FDG avid lesions. 18F-FDG PET/CT-based prognostic model includes PET/CT image, dominant clinical and pathological prognostic factors to predicting disease progression during chemotherapy or survival in NK/T-cell lymphoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03051555
Study type Interventional
Source Beijing Cancer Hospital
Contact Xuejuan Wang, MD
Phone 86 10-88196364
Email xuejuan_wang@hotmail.com
Status Not yet recruiting
Phase N/A
Start date March 1, 2017
Completion date December 31, 2020
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02878278 - Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation Phase 2
Terminated NCT01948180 - Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma Phase 2
Completed NCT00069238 - Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas Phase 2
Recruiting NCT03646422 - AEDV Registry of Primary Cutaneous Lymphoma
Terminated NCT02359162 - Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage Phase 3
Recruiting NCT02080234 - Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL Phase 2
Completed NCT03049449 - T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas Phase 1
Not yet recruiting NCT03051542 - Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma N/A
Recruiting NCT03154918 - GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma Phase 2
Recruiting NCT01933282 - MESA Treatment for NK/T Cell Lymphoma Phase 2
Terminated NCT02533323 - P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens Phase 2
Active, not recruiting NCT03439501 - Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] Phase 2
Recruiting NCT04417166 - Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma Phase 2
Recruiting NCT02859402 - Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas Phase 2